Acute myeloid leukemia

Acute myeloid leukemia (AML) be a cancer of de myeloid line of blood cells, wey be characterized by de rapid growth of abnormal cells wey dey build up insyd de bone marrow den blood den dey interfere plus normal blood cell production. Symptoms fi include feeling tired, shortness of breath, easy bruising, bleeding, den increased risk of infection. Occasionally, spread fi occur to de brain, skin, anaa gums. As an acute leukemia, AML dey progress rapidly, wey e be typically fatal within weeks anaa months if dem lef am untreated.

Risk factors dey include getting older, being male, smoking, previous chemotherapy anaa radiation therapy, myelodysplastic syndrome, den exposure to de chemical benzene. De underlying mechanism dey involve replacement of normal bone marrow plus leukemia cells, wich dey result in a drop insyd red blood cells, platelets, den normal white blood cells. Diagnosis generally dey base on bone marrow aspiration den specific blood tests. AML get chaw subtypes for wich treatments den outcomes fi vary.

De first-line treatment of AML usually be chemotherapy, plus de aim of inducing remission. People then fi go on to receive additional chemotherapy, radiation therapy, anaa a stem cell transplant. De specific genetic mutations present within de cancer cells fi guide therapy, as well as determine how long dat person likely be to survive.

Between 2017 den 2025, na dem approve 12 new agents for AML insyd de U.S., wey dey include venetoclax (BCL2 inhibitor), gemtuzumab ozogamicin (CD33 antibody-drug conjugate), den chaw inhibitors wey dey target FMS-like tyrosine kinase 3, isocitrate dehydrogenase, den oda pathways. Additionally, na dem introduce therapies like CPX351 den oral formulations of azacitidine den decitabine-cedazuridine. Ongoing research wey dey explore menin inhibitors den oda antibody-drug conjugates.

Na low-intensity treatment plus azacitidine plus venetoclax emerge as de most effective option give older anaa unfit AML patients, base on a network meta-analysis of 26 trials wey dey involve 4,920 participants. Na e show de highest survival den remission rates, plus low-dose cytarabine (LDAC) plus glasdegib den LDAC plus venetoclax sanso dey show clinical benefit.

Insyd 2015, na AML affect about one million people, wey na e result in 147,000 deaths globally. E most commonly dey occur in older adults. Males be affected more often dan females. De five-year survival rate be about 35% insyd people under 60 years old den 10% insyd people over 60 years old. Older people wey dema health be too poor for intensive chemotherapy get a typical survival of five to ten months. E dey account for roughly 1.1% of all cancer cases, den 1.9% of cancer deaths insyd de United States.

 References 

 External links 

 Childhood Acute Myeloid Leukemia Treatment at the US National Cancer Institute


Category:Articles wey dey contain video clips
Category:Translated from MDWiki